0 Items
Select Page

Severe Fever with Thrombocytopenia Syndrome Virus

Severe fever with thrombocytopenia syndrome virus (SFTSV) is a segmented, negative-strand RNA Phlebovirus belonging to the Bunyaviridae family. SFTSV is a newly identified bunyavirus, which was first recognised in China in 2009 (Yu, XJ). Since 2009, reported cases of SFTSV infection have increased dramatically, occurring predominantly in China, South Korea and Japan, but also in the United states and Mediterranean countries.  

Severe Fever with Thrombocytopenia Syndrome Virus Background

Severe Fevere with Thrombocytopenia Syndrome Virus (SFTSV) is a tick-borne virus that can be transmitted to humans by Haemaphysalis longicornis, a member of the Ixodidae family. H. longicornis, is endemic in the Asia-Pacific region and has a wide variety of hosts including livestock, birds, wild and domestic mammals. In some cases, animals infected with SFTSV do not exhibit clinical symptoms and are thought to act as intermediate reservoirs of the virus. Other ticks may act as vectors for SFTSV. However, bites from H. longicornis have been directly linked to cases of human SFTSV infection. Transmission of SFTSV from person-to-person has also been reported in some cases, due to contact with infected blood or mucus (Zhuang, L).

In humans the clinical symptoms associated with SFTSV infection include a high fever, abdominal pain, nausea, myalgia, a dramatic reduction of platelets and leukocytes, raised serum enzyme levels and, in some cases, multi-organ failure. Fatality rates due to SFTSV infection vary between 2- 30% and hospitalization may occur more frequently in the elderly and immunocompromised patients (WHO).

Currently, there is no licensed prophylactic vaccine or specific antiviral treatment for SFTSV infection. SFTSV is recognised by the World Health Organization as an emerging highly pathogenic virus, which presents a significant threat to human health.

References

Yu, XJ et al. (2011). Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. Apr 21;364(16):1523-32

Zhuang L et al. (2018). Transmission of Severe Fever with Thrombocytopenia Syndrome Virus by Haemaphysalis longicornis Ticks, China. Emerg Infect Dis. May;24(5).

World Health Organization: Risk assessment of human infection with a novel bunyavirus in China.

Severe Fever with Thrombocytopenia Virus Antigens

In support of research into this newly emerging virus we are pleased to have developed a recombinant Nucleoprotein antigen, using our mammalian expression system.  This protein may be applied for development of specific immunoassays and for studies into SFTSV biology.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

9 + 2 =

Live Customer Feedback

Join our mailing list

* indicates required